New HPV vaccine combo aims to fight Hard-to-Treat cancers
NCT ID NCT04432597
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39 adults with advanced or newly diagnosed HPV-related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HPV vaccine (PRGN-2009) and M7824 (a drug that targets PD-L1 and TGF-beta)
- What this could lead to
- If successful, this could offer a new treatment option for people with HPV-related cancers that are hard to treat, potentially improving immune response and tumor control.
- What could go wrong
- This is an early-phase trial with only 39 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Blood test may spare throat cancer patients from full radiation
- Can a Two-Antibody combo outsmart advanced cancer?